Clinical Research Directory
Browse clinical research sites, groups, and studies.
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sponsor: Sun Yat-sen University
Summary
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC.
Official title: Efficacy of HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma: an Observational, Real-world Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2021-01-01
Completion Date
2025-12-30
Last Updated
2025-02-06
Healthy Volunteers
No
Interventions
Hepatic arterial infusion chemotherapy
Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
Lenvatinib
12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Tislelizumab
200mg intravenously every 3 weeks
Toripalimab
240mg intravenously every 3 weeks
Sintilimab
200mg intravenously every 3 weeks
Camrelizumab
200mg intravenously every 3 weeks
Locations (1)
Chinese PLA General hospital
Beijing, Beijing Municipality, China